ResearcherBoston UniversityNo recent work listed
Steven C. Katz
Matched on ORCID iD 0000-0002-6030-9312; OpenAlex author ID A5040099847. Sources: ClinicalTrials.gov.
Their work
- Papers
- 3
- Trials
- 4 (principal investigator on 4)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2015: 1 trial · 2016: none · 2017: 1 trial · 2018: 1 trial · 2019: 1 trial · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 1 paper
Papers 3
- Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model. Co-author DOI 10.1016/j.surg.2023.05.011↗
- Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model. Co-author DOI 10.1007/s12672-022-00483-4↗
- Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. Co-author DOI 10.1016/j.surg.2020.04.059↗
Trials 4
- Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases Principal investigator NCT03818165↗
- CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC) Principal investigator NCT03682744↗
- CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer Principal investigator NCT02850536↗
- CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases Principal investigator NCT02416466↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Diego A. Vicente · 3 shared papers, 2020–2023 · strength 0.45
- Paper Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a m… DOI 10.1016/j.surg.2023.05.011↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Jayanth S. Shankara Narayanan · 3 shared papers, 2020–2023 · strength 0.45
- Paper Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a m… DOI 10.1016/j.surg.2023.05.011↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Rebekah Ruth White · 3 shared papers, 2020–2023 · strength 0.45
- Paper Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a m… DOI 10.1016/j.surg.2023.05.011↗
- Paper Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthoto… DOI 10.1007/s12672-022-00483-4↗
- Paper Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model. DOI 10.1016/j.surg.2020.04.059↗
- Benedict A. Capacio · 2 shared papers, 2020–2023 · strength 0.29
- Partha Ray · 2 shared papers, 2020–2022 · strength 0.26
- Suna Erdem · 2 shared papers, 2020–2022 · strength 0.26
- Richard David Schulick · 1 shared trial, 2017 · strength 0.22
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.